HS-10374-matched placebo tablets

DRUG5 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd., Hansoh BioMedical R&D Company

Conditions

PsoriasisPsoriatic Arthritis

Phase 1

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

CompletedNCT06033742

Jiangsu Hansoh Pharmaceutical Co., Ltd.Psoriasis

Start: 2021-11-13End: 2023-03-24Updated: 2023-09-13

Phase 2

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Hansoh BioMedical R&D CompanyPsoriasis

Start: 2023-09-28End: 2024-08-31Target: 120Updated: 2023-12-06

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

RecruitingNCT06176508

Hansoh BioMedical R&D CompanyPsoriatic Arthritis

Start: 2024-02-26End: 2026-08-28Target: 160Updated: 2024-07-18

A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

Not yet recruitingNCT06926582

Hansoh BioMedical R&D CompanyPsoriasis

Start: 2025-04-09End: 2026-12-09Target: 305Updated: 2025-04-13

Phase 3

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Not yet recruitingNCT06672393

Hansoh BioMedical R&D CompanyPsoriasis

Start: 2024-11-04End: 2026-06-29Target: 375Updated: 2024-11-04